| Janssen-Cilag AG - Trevicta 175 mg/0.875 ml, Depot-Injektionssuspension in einer Fertigspritze |
| 66054 | | 01 | | Trevicta 175 mg/0.875 ml | | Depot-Injektionssuspension in einer Fertigspritze | | N05AX13 | | Paliperidone | | 16.11.2016 | | |
|
| Composition |
| paliperidonum 175 mg ut paliperidoni palmitas 273 mg, polysorbatum 20, macrogolum 4000, acidum citricum monohydricum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, aqua ad iniectabile q.s. ad suspensionem pro 0.875 ml corresp. natrium 3.59 mg. |
| Packungsbestandteile |
| Retardsuspension zur intramuskulären Injektion | | | | | | | | Active Agent | Dose |
|---|
| Paliperidonum | 175mg / 0.875ml |
| | BAG: Active Agent | Dose |
|---|
| Paliperidonum | 175 mg |
| | | | Inactive agents | Dose |
|---|
| Citric Acid Monohydrate | | | Macrogol | 4000 | | Sodium Dihydrogenophosphate Monohydrate | | | Sodium Hydroxide | | | Polysorbatum 20 | |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 666.22 | 740.95 | B | SL | Yes |
|
